M
Martin S. Tallman
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 948
Citations - 71451
Martin S. Tallman is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 117, co-authored 917 publications receiving 60011 citations. Previous affiliations of Martin S. Tallman include University of Rome Tor Vergata & University of Toronto.
Papers
More filters
Journal ArticleDOI
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900
Mithat Gonen,Zhuoxin Sun,Maria E. Figueroa,Jay P. Patel,Omar Abdel-Wahab,Janis Racevskis,Rhett P. Ketterling,Hugo Fernandez,Jacob M. Rowe,Jacob M. Rowe,Martin S. Tallman,Ari Melnick,Ross L. Levine,Elisabeth Paietta +13 more
TL;DR: It is concluded that CD25(POS) status provides prognostic relevance in AML independent of known biomarkers and is correlated with stem cell gene-expression signatures associated with adverse outcome in AMl.
Journal ArticleDOI
Role of the p38 Mitogen-Activated Protein Kinase Pathway in the Generation of Arsenic Trioxide–Dependent Cellular Responses
Nick Giafis,Efstratios Katsoulidis,Antonella Sassano,Martin S. Tallman,Linda S. Higgins,Angel R. Nebreda,Roger J. Davis,Leonidas C. Platanias +7 more
TL;DR: Evidence is provided that the kinases MAPK kinase 3 (Mkk3) and Mkk6 are activated during treatment of leukemic cell lines with As(2)O(3) to regulate downstream engagement of the p38 mitogen-activated protein kinase.
Journal ArticleDOI
Musashi2 sustains the mixed-lineage leukemia–driven stem cell regulatory program
Sun Mi Park,Mithat Gonen,Ly P. Vu,Gerard Minuesa,Patrick Tivnan,Trevor S. Barlowe,James Taggart,Yuheng Lu,Raquel P. Deering,Nir Hacohen,Maria E. Figueroa,Elisabeth Paietta,Hugo F. Fernandez,Martin S. Tallman,Ari Melnick,Ross L. Levine,Christina S. Leslie,Christopher J. Lengner,Michael G. Kharas +18 more
TL;DR: It is demonstrated that conditional deletion of Msi2 in the hematopoietic compartment results in delayed leukemogenesis, reduced disease burden, and a loss of LSC function in a murine leukemia model and suggested MSI2 as a potential therapeutic target for myeloid leukemia.
Journal ArticleDOI
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.
Jessica K. Altman,James M. Foran,Keith W. Pratz,Denise Trone,Jorge E. Cortes,Martin S. Tallman +5 more
TL;DR: There were no apparent additional toxicities with addition of quizartinib to chemotherapy although grade ≤1 QT prolongation was observed at MTD and maximum tolerated dose (MTD) was identified as DL‐1.
Journal ArticleDOI
AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies
Eytan M. Stein,Jessica K. Altman,Robert H. Collins,Daniel J. DeAngelo,Amir T. Fathi,Ian W. Flinn,Arthur E. Frankel,Ross L. Levine,Bruno C. Medeiros,Manish Patel,Daniel A. Pollyea,Gail J. Roboz,Richard Stone,Ronan T. Swords,Martin S. Tallman,Sam Agresta,Bin Fan,Hua Yang,Katharine E. Yen,Stéphane de Botton +19 more
TL;DR: AG-221, a potent, selective, oral inhibitor of mutated IDH2, is well tolerated in patients with advanced hematologic malignancies, and triggers the differentiation of leukemic blast cells that ultimately leads to objective durable responses, including complete remissions.